title: Cytokine-directed therapies for the treatment of chronic airway diseases.
abstract: Multiple cytokines play a critical role in orchestrating and perpetuating inflammation in asthma and chronic obstructive pulmonary disease (COPD) and several specific cytokine and chemokine inhibitors now in development as future therapy for these diseases. Anti-IL-5 antibody markedly reduces peripheral blood and airway eosinophils, but does not appear to be effective in symptomatic asthma. Inhibition of IL-4 despite promising early results in asthma has been discontinued and blocking IL-13 might be more effective. Inhibitory cytokines, such as IL-10, interferons and IL-12 are less promising, as systemic delivery produces side effects. Inhibition of TNF-alpha may be useful in severe asthma and for treating severe COPD with systemic features. Many chemokines are involved in the inflammatory response of asthma and COPD and several small molecule inhibitors of chemokine receptors (CCR) are in development. CCR3 antagonists (which block eosinophil chemotaxis) and CXCR2 antagonists (which block neutrophil and monocyte chemotaxis) are in clinical development for asthma and COPD, respectively. Because so many cytokines are involved in asthma, drugs that inhibit the synthesis of multiple cytokines may prove to be more useful; several such classes of drug are now in clinical development and any risk of side effects with these non-specific inhibitors may be reduced by the inhaled route.
authors.affiliation: Department of Thoracic Medicine, National Heart & Lung Institute, Imperial College, Dovehouse St, London SW3 6LY, UK. p.j.barnes@ic.ac.uk
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Barnes
mesh_terms: D000305:Adrenal Cortex Hormones / Q000378:metabolism; D000818:Animals; D001249:Asthma / Q000378:metabolism; D018925:Chemokines / Q000037:antagonists & inhibitors / Q000378:metabolism; D016207:Cytokines / Q000096:biosynthesis* / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation; D007372:Interferons / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D018664:Interleukin-12 / Q000378:metabolism; D018793:Interleukin-13 / Q000378:metabolism; D015847:Interleukin-4 / Q000037:antagonists & inhibitors / Q000378:metabolism; D015848:Interleukin-5 / Q000378:metabolism; D016906:Interleukin-9 / Q000378:metabolism; D016210:Methacholine Chloride / Q000378:metabolism; D008954:Models, Biological; D009504:Neutrophils / Q000378:metabolism; D029424:Pulmonary Disease, Chronic Obstructive / Q000628:therapy*; D018418:Th2 Cells / Q000378:metabolism; D013997:Time Factors
chemical_list: D000305:Adrenal Cortex Hormones; D018925:Chemokines; D016207:Cytokines; D018793:Interleukin-13; D015848:Interleukin-5; D016906:Interleukin-9; D016210:Methacholine Chloride; D016753:Interleukin-10; D018664:Interleukin-12; D015847:Interleukin-4; D007372:Interferons